Dyslipidemia Flashcards

1
Q

What is the rate limiting step of the formation of cholesterol?

A

The conversion of β -hydroxyl-β -methylglutaryl
coenzyme A (HMG-CoA) to mevalonic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which lipids that serve as an important source of stored energy in adipose tissue?

A

Triglycerides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the most common type of heart disease in the U.S?

A

Coronary artery disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

True or false: HDL-C is inversely related to CHD risk

A

False

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What test is often used to diagnose dyslipidemia?

A

Fasting lipid panel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the Friedewald equation? What is it used for?

A

. LDL = TC – HDL – (TG/5)
. Calculate LDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the main protein component of LDL?

A

Apo B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

In what population should FLPs be routinely checked?
a. 20-50
b. 30-50
c. 20+
d. 30+

A

c. 20+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How often should a FLP be taken?

A

At least once every 5 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

True or false: The Framingham 10 year CHD risk tool is a fully comprehensive tool currently used to assess ASCVD risk

A

False. Currently the 10 year ASCVD risk tool, which is more comprehensive than the Framingham

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Which of the following is an appropriate goal of dyslipidemia therapy?
a. Raise TC and lower LDL
b. Raise TC and LDL
c. Lower TC and raise LDL
d. Lower TC and LDL

A

d. Lower TC and LDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Select all treatments that are currently more recommended according to current guidelines?
▪HMG-CoA Reductase Inhibitors (Statins)
▪Cholesterol Absorption Inhibitor
▪Niacin
▪Apo B Antisense Oligonucleotides
▪Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors
▪Microsomal Triglyceride Protein Inhibitors

A

▪HMG-CoA Reductase Inhibitors (Statins)
▪Cholesterol Absorption Inhibitor
▪Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Which HMG-CoA reductase inhibitors are prodrugs?

A

Lovastatin and simvastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the most common adverse effect of HMG-CoA reductase inhibitors?

A

Myalgia (muscle pain)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which statin drug and at what dose is highly associated with rhabdomyolysis?

A

Simvastatin 80mg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Which of the following HMG-CoA reductase inhibitors is the most lipophilic?
a. Fluvastatin
b. Lovastatin
c. Pravastatin
d. Rosuvastatin

A

b. Lovastatin

17
Q

What is the recommended course of action for unexplained severe muscle symptoms or fatigue developing during statin therapy?

A

Promptly discontinue the statin

18
Q

What is the recommended course of action for mild to moderate muscle symptoms developing during statin therapy?

A

Discontinue the statin until the symptoms can be evaluated. Consider alternative statin

19
Q

Moderate intensity statins reduce LDL by about what percent?

A

30-49%

20
Q

Low intensity statins reduce LDL by about what percent?

A

< 30%

21
Q

High intensity statins reduce LDL by about what percent?

A

Greater than or equal to 50%

22
Q

Which statins and at what dose are classified as high intensity?

A

. Atorvastatin 40, 80mg
. Rosuvastatin 20, 40mg

23
Q

What is the rule of 6?

A

Every doubling of statin dose develops, on average, a further 6% reduction in LDL cholesterol. For this reason ACC/AHA guidelines recommend starting statin therapy at max tolerated dose

24
Q

True or false: Dyslipidemias play an important role in the pathogenesis of ASCVD

A

True

25
Q

Dyslipidemia is defined as…

A

▪ Elevated total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, or triglycerides
▪ Low high-density lipoprotein (HDL) cholesterol
▪ A combination of these abnormalities

26
Q

Blockage in the arteries that supply the heart or brain may result in what?

A

Heart attack or stroke

27
Q

For every 1% increase in blood cholesterol levels, there is a _____ increase in the risk of ASCVD

A

1-2%

28
Q

When can the Friedewald equation not be used to calculate LDL?

A

If TG levels are >400mg/dL

29
Q

Ezetimibe MOA

A

Selectively inhibits the absorption of cholesterol on the brush border of the small intestine

30
Q

Contraindications of bile acid sequestrants

A

. Triglycerides >300mg/dL
. Hypertriglyceridemia induced pancreatitis

31
Q

Welchol drug classification and MOA

A

Bile acid sequestrant. Anion exchange resins that bind bile acid in the intestinal lumen, forming a complex that is excreted in the feces

32
Q

True or false: Gemfibrozil should not be initiated in patients on statin therapy because of an increased risk for muscle symptoms and rhabdomyolysis

A

True

33
Q

Vascepa drug classification and MOA

A

Omega 3 fatty acid. MOA is unknown, but this class is thought to reduce synthesis of TGs

34
Q

Repatha drug classification and MOA

A

PCSK9 inhibitor. Binds to and inhibits PCSK9, binding to LDL receptors preventing the degradation of the receptors and promoting clearance of circulating LDL

35
Q

Nexletol drug classification and MOA

A

Bempedoic acid. ACL inhibitor that inhibits cholesterol synthesis in the liver

36
Q

How many statin benefit groups are there?

A

4

37
Q

What is the immediate secondary prevention plan for individuals with clinical ASCVD?

A

High intensity statin